AnGes MG, Vical to Collaborate in Developing Genomic Drug for Skin Cancer.Tokyo, Japan, May 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - AnGes MG announced on May 30 that it has signed a collaboration agreement with US bio venture company Vical for Allovectin-7, Vical's proprietary immunotherapeutic for malignant melanoma Malignant Melanoma Definition Malignant melanoma is a type of cancer arising from the melanocyte cells of the skin. Melanocytes are cells in the skin that produce a pigment called melanin. . Allovectin-7 (A-7), which consists of a DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. plasmid, can induce tumor immunity, suppressing the growth of cancer. Under the agreement terms, AnGes MG will support phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the while receiving the right to develop and market A-7 in Asia. Further, the two companies will share data and knowledge on A-7. In addition, the partners have concluded a strategic agreement under which AnGes MG will offer Vical $22.6 million for phase III clinical trials. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion